Quartz·2 min read·medium
Amgen's cancer drug combo cut death risk by 58% in lung cancer trial
✦AI Summary
A clinical trial for Amgen's Imdelltra combined with AstraZeneca's Imfinzi showed a significant increase in survival rates for lung cancer patients. The combination therapy extended median survival to 21.1 months compared to 12.7 months for the monotherapy.
Why it matters
This represents a major advancement in oncology treatment options for lung cancer patients.
Median survival reached 21.1 months with Imdelltra plus…
Also covering this story
One other newsroom covered this event. We read that version too.
healthscience
✦
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in